Sparsentan shows mixed results in FSGS Phase 3 trial compared to irbesartan, revealing key benefits and trial design challenges.
Sleep deprivation can lead to decreased cognitive function and impaired motor skills, affecting individuals who work in high-pressure…
Narcolepsy treatment breakthrough as FDA approves Takeda's oral drug Orzeyful, offering the first therapy to target all type…
Sparsentan shows mixed results in FSGS Phase 3 trial compared to irbesartan, revealing key benefits and trial design…
Sparsentan FSGS treatment offers a new FDA‑approved option for focal segmental glomerulosclerosis, prompting clinicians to compare it with…
Journavx revenue surged as Vertex Pharmaceuticals reported $3.33 billion Q2 earnings, driven by the new acute pain drug’s…
Discover how ALK-positive lung cancer treatment is evolving with new inhibitors, improving survival for thousands of patients worldwide.
Biosimilars reduce drug costs by up to 70%, but patient access depends on insurance coverage and policy decisions.
Discover how obesity medications like semaglutide may help manage metabolic side effects from antipsychotics.
Learn why user access to Yesafili, a biosimilar for eye conditions like wAMD, may be restricted and how…
Zambia's delay in signing a health memorandum with the US stems from disagreements over data and specimen sharing,…
